Eugia Pharma Receives USFDA Approval for Doxercalciferol Injection 2 mcg/1 mL & 4 mcg/2 mL
Published: January 24, 2022
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Doxercalciferol Injection 2 mcg/1 mL & 4 mcg/2 mL.
Indications for this product include:
- Secondary hyperparathyroidism in adult patients with CKD on dialysis.